Bio-Plexus receives FDA approval for Winged Set.

TOLLAND, Conn.--(BUSINESS WIRE)--July 1, 1996--Bio-Plexus, Inc., (NASDAQ/NMS:BPLX), designer, developer, manufacturer and marketer of safety medical products under the Punctur-Guard(R) name, announced today that it has received 510(k) approval from the U.S. Food and Drug Administration to market the Punctur-Guard(R) Winged Set.

Domestic market size for the safety winged set is estimated at approximately $140 million per year. Marketing of the product will begin immediately.

The winged set consists of a small needle with a pair of plastic wings that gives the healthcare worker a greater ability to control the needle for very precise vein insertion. It is used primarily to draw blood from patients whose veins are difficult to access, typically geriatric or pediatric patients. As with the Punctur-Guard(R) blood collection needle, the winged set enters the patient sharp and is removed blunt, minimizing a healthcare worker's exposure to the sharp, contaminated needle.

"We are very excited about our ability to market this new safety needle. Field testing has shown significant interest in the winged set and this addition to our product line should accelerate revenue growth," said Ronald A. Haverl, chief executive officer of Bio-Plexus.

CONTACT: Bio-Plexus, Inc.

Christina Tamburro, 203/871-8601

or

Porter, Le Vay & Rose, Inc.

Marilynn Meek, 212/564-4700